<DOC>
	<DOC>NCT00133887</DOC>
	<brief_summary>In a population of kidney transplant recipients having developed a first squamous cell carcinoma, the aim of the study is to assess the incidence of subsequent skin cancers over 2 years in patients who are switched to rapamycin as compared to patients who are maintained under calcineurin inhibitors.</brief_summary>
	<brief_title>TUMORAPA 1: Efficacy of Rapamycin in Secondary Prevention of Skin Cancers in Kidney Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Skin Neoplasms</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<criteria>First posttransplant squamous cell carcinoma in a kidney transplant recipient under calcineurin inhibitors Other squamous cell carcinomas in the past history More than 2 transplantations Patients not under calcineurin inhibitors Unstable graft function Non controlled hyperlipidemia (cholesterol &gt; 7.8 mmol/l or triglycerides &gt; 3.95 mmol/l) Leucopenia &lt; 3000/mm3 Thrombocytopenia &lt; 100,000/mm3 Liver dysfunction Pregnancy Allergy to macrolides</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Squamous cell carcinoma</keyword>
	<keyword>kidney transplant recipients</keyword>
	<keyword>rapamycin</keyword>
	<keyword>Skin cancers in kidney transplant recipients</keyword>
</DOC>